Generic vs. Branded: Exploring Awareness, Perceptions, and Preferences for Generic Medicines among the People of Mandi
Background: Generic medicines, being pharmaceutically equivalent to branded drugs in terms of safety, dosage, efficacy, and quality, offer a cost-effective alternative to branded medications. Despite governmental promotion through schemes like Jan Aushadhi, public skepticism persists, particularly in rural and semi-urban areas, due to misconceptions about their safety and effectiveness. This study investigates the level of awareness, perceptions, and preferences related to generic medicines among residents of Mandi district, Himachal Pradesh. Materials and Methods: A descriptive, cross-sectional study was conducted between January and March 2025 using a structured online questionnaire. A total of 400 adult residents from both rural and urban areas of Mandi participated. The questionnaire, administered in Hindi and English via Google Forms, captured data on demographics, awareness, perceptions, and usage behavior regarding generic versus branded medicines. Descriptive statistics and categorical analysis were performed using SPSS v26.0. Results: The majority of respondents (40.5%) were aged 26–35 years, with 66.5% from rural areas and 35.8% educated up to secondary school. Awareness about generics was relatively strong: 77.3% correctly identified generic drugs, 87.8% recognized them as more affordable, and 74% agreed they are as effective as branded medicines. However, only 65.8% expressed full trust in generics, and just 59.5% reported that doctors commonly recommend them. A total of 31.8% scored “Very Good” on knowledge and perception, while 27% fell into “Fair” or “Poor” categories, mainly among less educated and lower-income groups. Conclusion: While the findings indicate growing awareness of generic medicines in Mandi, significant trust and knowledge gaps remain particularly concerning safety, regulation, and physician advocacy. To foster wider acceptance, culturally tailored education, stronger provider engagement, and clearer regulatory communication are essential. Bridging these gaps will enhance the uptake of generics and advance equitable access to affordable healthcare.